Advertisement

Topics

Latest Drug Discovery NewsRSS

10:35 EDT 20th September 2017 | BioPortfolio

MedLever to Showcase Radiation Oncology Applications at ASTRO 2017

Interoperability with Oncology-specific EMRs Streamlines Workflow MedLever today announced it will be demonstrating its breakthrough platform and applications that simplify clinical workflow, enable interoperability, and enhance clinical and scientific research September 24-26 in San Diego, CA at the 2017 American Society for Radiation Oncology (ASTRO)...

ROTH Capital Partners Announces the Addition of Jotin Marango, M.D., Ph.D. and Yasmeen Rahimi, Ph.D. to its Healthcare Research Team

ROTH Capital Partners (“ROTH”), www.roth.com, a full service investment bank focused on serving emerging growth companies and their investors, today announced that Jotin Marango, M.D., Ph.D. and Yasmeen Rahimi, Ph.D. have joined the firm’s healthcare research team. Dr. Marango is a Managing Director and Senior Research Analyst covering ...

Cellular Dynamics International Signs Agreement with Nanion Technologies to Enhance Mutual Offerings for Researchers

Cellular Dynamics International (CDI), a FUJIFILM company, the leading developer and manufacturer of differentiated cells derived from human induced pluripotent stem cells (iPSCs), and Nanion Technologies GmbH (Nanion), a leading provider of instrumentation for ion channel drug discovery and screening, announced today that they have entered into a

STAT Plus: What to watch for when Zogenix and Amicus disclose important clinical trial results

It's time to prep for important — and stock-moving — data releases from Zogenix and Amicus Therapeutics.

Global Drug Delivery Coating Market Research Report Forecast 20172022 [Report Updated: 29062017] Prices from USD $2800

Delivery of the Report will take 4872 hours once order is placed.The Global Drug Delivery Coating Market Research Report Forecast 20172022 is a valuable source of insightful data for business strategists. It provides the Drug Delivery Coating industry overview with growth analysis and historical futuristic cost, revenue, demand and supply data as applicable. The research analysts provide an ela...

Generex Announces New Clinical Trial of Hema Diagnostic Systems’ Rapid 1-2-3® Tuberculosis Point-of-Care Tests

International Institutions Collaborating on Trial Generex Biotechnology Corporation (OTCPink:GNBT) (www.generex.com) today announced the participation by its subsidiary, Hema Diagnostic Systems LLC (www.hemadiagnosticsystems.com), in a diagnostic clinical

BioSensics™ Has Received over $2.5M in Grant Funding from the NIH to Develop a Novel Telecare Solution for Huntington’s Disease

BioSensics, a leader in developing wearable sensor technologies for clinical research and medical applications, has received grant funding from the National Institutes of Health (NIH) to develop HDWear, a novel telecare solution for Huntington’s disease. HDWear, powered by BioSensics’ PAMSys sensor technology, will enable continuous remote monitoring o...

FDA Indicates That Jaguar’s Canalevia Drug Product Candidate Qualifies as “Minor Use” for Exercise-Induced Diarrhea (EID) in Dogs, Rendering Canalevia Eligible for Conditional Approval for This Indication

Jaguar Expects to Conduct the Commercial Launch of Canalevia in the First Half of 2018 for EID and CID (Chemotherapy-Induced Diarrhea) in Dogs, Dependent on Receiving Conditional Approval for These Indications Jaguar Health, Inc. (NASDAQ:JAGX) (Jaguar), a natural-products pharmaceuticals company focused on developing and commercializing novel, sustaina...

CBRE/NE Announces Corbus Pharmaceuticals Triples Its Footprint in Norwood

New lease signed for 32,733 SF at 500 River Ridge Drive CBRE/New England today announced that Corbus Pharmaceuticals has strengthened its relationship with Cornerstone Corporation, entering into an agreement with the management agent for River Ridge Office Park, to expand and relocate within River Ridge Office Park in Norwood, Mass. The Phase...

STAT Plus: Pharmalittle: Alnylam gets a big clinical trial win; states expand their opioid probes

An Alnylam drug for a rare nerve disorder hit targets in late-stage studies, and U.K. regulators recommend Opdivo for some cancers.

PDE Inhibitor Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, PDE InhibitorMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across PDE Inhibitor. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products. A comparative pipeline therapeutics assessment of PDE Inhibitor by development stage,...

N-of-One to Incorporate New AMP Guidelines on Somatic Cancer Variants into its Best-in-Class Curation and Reporting for Patient-Specific Oncology Decision Support

N-of-One, Inc., the leader in clinical interpretation of molecular tests in oncology, is proud to announce the incorporation of the recent AMP guidelines on reporting somatic cancer variants with enhanced levels of evidence (LOE) into N-of-One’s existing curation and reporting. In December of 2016, to address the field’s need for consistent interpretat...

Cybrexa Therapeutics Appoints Vishwas Paralkar, Ph.D. as Chief Scientific Officer

Dr. Paralkar will lead the drug development effort for Cybrexa’s tumor targeting technology. New Haven, CT (PRWEB) September 20, 2017 Cybrexa Therapeutics, a start-up cancer therapeutics company, announced today that it has appointed Vishwas Paralkar to the role of chief scientific officer. In this role, Dr. Paralkar will lead the development of Cybrexa’s tumor targeting technology. He will r...

Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor

Introducing a new therapeutic approach for patients with movement disorders Cavion, Inc. announced today that the first patient has been enrolled in its new T-CALM Study (Tremor Cav3 Modulation Study), a

Stryker’s Spine Division Receives FDA Clearance for 3D-Printed Tritanium® C Anterior Cervical Cage

Stryker’s Spine division today announced that its Tritanium® C Anterior Cervical Cage, a 3D-printed interbody fusion cage intended for use in the cervical spine, has received 510(k) clearance from the U.S. Food and Drug Administration. The Tritanium C Anterior Cervical Cage is constructed from Stryker’s proprietary Tritanium In-Growth ...

Alzheon to Make Keynote and Featured Presentations at Upcoming Scientific and Industry Conferences

Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer’s disease and other neurological and psychiatric disorders, today announced that the company will be making keynote and featured presentations at several scie

Alpine Immune Sciences Announces Poster Presentation at 2017 ACR/ARHP Annual Meeting

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading immunotherapy company focused on developing treatments for autoimmune/inflammatory diseases and cancer, today announced a planned poster presentation highlighting recent data from a preclinical study evaluating dual ICOS/CD28 antagonists generated by the Company’s vlgD™ platform at the upcoming 2017...

Selexis SA, Spinomix SA and the University of Lausanne Publish Novel, High-Throughput Technology Process for Isolation of High Secretion CHO Cell Clones

Paper in Biotechnology and Bioengineering describes faster and more efficient technology for isolation of high-production CHO cell lines for use in manufacturing biologics Selexis SA and Spinomix SA announced today the publication of their collaborative work

InVivo Therapeutics to Present at Ladenburg Thalmann 2017 Healthcare Conference

InVivo Therapeutics Holdings Corp. (NVIV) today announced that Mark Perrin, Chief Executive Officer and Chairman, will present at the Ladenburg Thalmann 2017 Healthcare Conference on Tuesday, September 26, 2017 at 12:00pm ET at the Sofitel New York Hotel, in Manhattan. Mr. Perrin’s presentation will provide an overview of the company and discuss recent u...

bluebird bio Appoints Mary Lynne Hedley, Ph.D. to Board of Directors

bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies for cancer, today announced that it has appointed Mary Lynne Hedley, Ph.D. to its Board of Directors. “I’m

Nativis to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Updates to include partnerships, clinical program progress and plans for 2018 Nativis, Inc., a clinical stage life science bio-electronics company developing non-invasive, safe and highly effective treatments for cancers and other serious diseases, today announced that Chris E. Rivera, Nativis Chief Executive Officer, is scheduled to present at the

Global Ovulation Test Market Data Survey Report 2025 [Report Updated: 25072017] Prices from USD $1500

SummaryOvulation tests or ovulation predictor kits OPKs are tests that allow users to predict ovulatory period. Ovulation tests work by detecting luteinizing hormone LH. Just preceding ovulation, women experience an "LH surge" a sudden, dramatic, and brief rise in the level of luteinizing hormone.The global Ovulation Test market will reach xxx Million USD in 2017 with CAGR xx% from 20182025. The ...

Nucleotide Analog Reverse Transcriptase Inhibitor NtRTIs Pipeline Insights, 2017 [Report Updated: 01092017] Prices from USD $1250

DelveInsight's, Nucleotide Analog Reverse Transcriptase Inhibitor NtRTIsMechanism of action Insights, 2017, report provides comprehensive insights of the ongoing therapeutic research and development across Nucleotide Analog Reverse Transcriptase Inhibitor NtRTIs. The report provides a complete understanding of the pipeline activities covering all clinical, preclinical and discovery stage products....

Dicerna to Participate in Fireside Chat at the LEERINK Partners Roundtable Series

Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that Douglas M. Fambrough, Ph.D., president and chief executive officer, will participate in an analyst-led fireside chat at the LEERINK Partners Roundtable Series: Rare Disease and Immuno-Oncology on Wedne...

Avista Pharma Earns Carolina Star Safety Award

CDMO Achieves Highest Level Of Safety And Health Certification Avista Pharma Solutions, Inc. (“Avista Pharma”) has announced that its Durham, North Carolina facility has achieved Carolina Star status, the

Quick Search
Advertisement
 

review and buy Drug Discovery market research data and corporate reports here